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Introduction  
Extensive childhood dermatosis are often a challenge owing to their potential impact in the child’s psychological development and the need of safe therapeutic alternatives given the importance of avoiding 
systemic agents’ toxicity. Phototherapy is therefore widely used as a safe alternative treatment option for photoresponsive dermatosis such as psoriasis, vitiligo, pityriasis lichenoides, alopecia areata (AA) or 
atopic eczema2,3.  
Several phototherapeutic options are available – narrowband UVB (UVB-nb), broadband UVB (UVB-bb), systemic and topic psoralen-UVA photochemotherapy (PUVA and topic PUVA, respectively) and 
excimer laser therapy3 – which are selected on a case-to-case basis according to diagnosis, disease severity, skin phototype and age.  
Treatment protocol ranges from 2 to 5 weekly sessions, starting with 70% of the predetermined minimal erythema dose (MED) for UVB and 75% of the minimal phototoxic dose (MPD) for UVA, with an 
increase of 10-20% at each session1,2 if no erythema occurs.  
Objective and Methods  
This observational retrospective study aims to assess the efficacy and safety of phototherapy to treat moderate to severe dermatological conditions in our paediatric population. 
Relevant clinical data relative to patients aged ≤ 18 years treated with phototherapy over the last 17 years was collected from phototherapy charts and clinical records (January 1996 to December 2012). 
Patients treated with UVB between 2006-2009 were excluded, as the equipment did not allow quantification of the radiation dose in J/cm2 (21 patients).  
Treatment was administered according to a standardized protocol – starting at 0,08 J/cm2 with 10% dose increase at each session for UVB and at 0,5 J/cm2 with subsequent increase of 0,5 J/cm2 for UVA. 
MED and MPD were not calculated routinely. Statistical analysis was performed with Gnu S and Excel. 
Discussion 
Of the 37 psoriasis patients treated, 83,3% improved and 16,7% withdrew the treatment. Alopecia areata and vitiligo patients had lower response rates – 55,6% and 33,3%, and also higher 
withdrawal rate – 19,4% and 55,5%, respectively. Furthermore, psoriasis patients did significantly less treatments per cycle and shorter cycles (p<0.05) and had globally better outcomes (p<0.05) 
when compared to other diagnosis, as concluded by previous published data1,2,3. 
We recognize the lack of assessment of long term oncogenic risk, namely for PUVA patients, as a limitation of this study. On the other hand, the diagnosis prevalence might have been skewed by 
the exclusion of 21 patients treated with UVB for a period of time (which explains the small group of atopic eczema patients included). 
According to our data, phototherapy appears to be a safe and effective option for childhood photoresponsive dermatosis, specially psoriasis, without significant difference between its clinical type. 
However, the significant withdrawal rate and scholar absenteeism might be an important limitation. 
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Results 
78 children met the inclusion criteria, of which 50 (64%) 
were female. Mean age was 13 years (range 2-18). 
Personal and familiar medical history remarks are 
summarized on table 1. 
Phototype III was the most prevalent (42; 53,8%), followed 
by II (23; 29,5%), IV (14,1%) and V (2; 2,6%). None was 
classified as phototype I. 
Distribution according to diagnosis is shown on graphic 1. 
All children were previously and concomitantly treated with 
topical agents. Systemic agents used before and during 
phototherapy treatment are shown on table 1. 
Graphic 1 – Number of patients with each diagnosis 
Short term side effects (table 1) occurred in 16 patients (21%), were mild to moderate 
and none led to therapeutic interruption. No significant statistical correlation was found 
between side effects and phototype or concomitant systemic therapeutics (p>0.05).  
Topical and systemic PUVA were the first choice in 37% and 40% of the patients respectively, while 
nb-UVB and bb-UVB were used in 11,5% each. The mean number of cycles was 1,5 (range 1-7) 
with an average of 16,3 treatments per cycle and a mean cumulative dose of 107 (UVA) and 17 J/
cm2 (UVB). 71% were treated with one single cycle. Type and characteristics of phototherapy 
treatment and the respective outcome for each specific diagnosis are summarized on tables 2-6. 
Table 1 – Population characteristics and outcomes according to diagnosis Tables 2-6 – Type and characteristics of phototherapy treatment for psoriasis, alopecia areata and vitiligo  
